undamentalytics Newsletter
Sign in

Monte Rosa Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Monte Rosa Therapeutics, Inc. had total assets of $449m, total liabilities of $216m and shareholders' equity of $233m. It held $130m in cash against $0 of debt: net cash of $130m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents12822413090
Total current assets236377393631
Total assets304439449691
Accounts payable111747
Deferred revenue (current)181173022
Total current liabilities471576460
Total debt0000
Total liabilities125216216204
Shareholders' equity179223233487
Net debt (negative = net cash)−128−224−130−90
Shares outstanding50m62m—85m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: GLUE vs TNXPARCT vs GLUEGLUE vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Monte Rosa Therapeutics, Inc.